Table 5.
Comparisons with 2016 UK NAFLD Survey.
| Sheridan et al.14 |
Current study |
||
|---|---|---|---|
| 2016 | 2019 | 2022 | |
| Local liver disease pathway | 22% | 85% | 88% |
| Main indication for referral into secondary care | Abnormal LFTs | Abnormal LFTs | Abnormal LFTs |
| Non-invasive fibrosis assessment tools used in secondary care | |||
| AST:ALT ratio | 53% | Not captured | Not captured |
| Fib-4 score | 16% | 17% | 18% |
| NAFLD fibrosis score | 41% | 3% | 1% |
| APRI score | 6% | Not captured | Not captured |
| ELF or other serum fibrosis markers | 5% | 5% | 7% |
| Fibroscan | 50% | 72% | 75% |
| BMI documentation∗ | 83% | 76% | 71% |
| Alcohol history documentation∗ | 79% | 80% | 75% |
| Alcohol advice∗ | 71% | 32% | 45% |
| Dietary advice∗ | 93% | 26% | 45% |
| Exercise advice∗ | 94% | 51% | 59% |
| Weight loss target advice given∗ | 50% | 29% | 35% |
ALT, alanine aminotransferase; APRI, AST to Platelet Ratio Index; AST, aspartate aminotransferase; FIB-4, Fibrosis-4; NAFLD, non-alcoholic fatty liver disease.
∗
Metrics not directly comparable as 2016 study was a qualitative survey and current study measured practice.